本帖最后由 老马 于 2012-1-13 21:20 编辑
, x* j' D4 B) {' \; T" w% @& d
( h' n' X0 j$ \, s: x B9 r爱必妥和阿瓦斯丁的比较
1 Z+ g/ F3 }* v0 I
L6 e2 K! q& Y; R3 d
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/* x L2 [6 j( Z8 u- l; L6 M+ P
& g" p1 {& ?! `9 u
% ?% L+ Q1 Q- N' }6 y# [6 K
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/: [/ |! y5 S( h4 E# V' c6 x
==================================================0 v* M: s" N0 D. j; ?/ ` L" x/ n5 X
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& n9 U( |$ p a9 c8 SPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.% M5 A- `. b1 \9 F" y. |7 x2 w
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 M1 y3 C1 y, k7 \& {! L
|